CD30 in systemic mastocytosis

Immunology and Allergy Clinics of North America

Volumn 34, Issue 2, 2014, Pages 341-355

  Van Anrooij, Bjorn ^a   Kluin, Philip M ^a   Oude Elberink, Joanne N G ^a   Kluin Nelemans, Johanna C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

CD153; CD30; CD30 ligand; Soluble CD30; Systemic mastocytosis

Indexed keywords

BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; CD30 LIGAND; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; ANTIBODY; TNFSF8 PROTEIN, HUMAN;

ADAPTIVE IMMUNITY; ALLERGIC DISEASE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL PROLIFERATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE MARKER; DRUG TARGETING; HODGKIN DISEASE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; LARGE CELL LYMPHOMA; MAST CELL; MAST CELL LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC MASTOCYTOSIS; ADULT; ANTAGONISTS AND INHIBITORS; B LYMPHOCYTE; BLOOD; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MASTOCYTOSIS, SYSTEMIC; PATHOLOGY; PROGNOSIS; T LYMPHOCYTE;

ADULT; ANTIBODIES; ANTIGENS, CD30; B-LYMPHOCYTES; CD30 LIGAND; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOCYTE ACTIVATION; MAST CELLS; MASTOCYTOSIS, SYSTEMIC; PROGNOSIS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84898770549     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2014.01.006     Document Type: Review

References (93)

1. Schwab U., Stein H., Gerdes J., et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982, 299(5878):65-67.
2. Savage K.J., Harris N.L., Vose J.M., et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the international peripheral T-cell lymphoma project. Blood 2008, 111(12):5496-5504.
3. Swerdlow S.H. International Agency for Research on Cancer. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, vol. 15:439. International Agency for Research on Cancer IARC, Lyon (France). 4th edition.
4. Durkop H., Latza U., Hummel M., et al. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992, 68(3):421-427.
5. Smith C.A., Gruss H.J., Davis T., et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993, 73(7):1349-1360.
6. Romagnani S., Del Prete G., Maggi E., et al. CD30 and type 2 T helper (Th2) responses. JLeukoc Biol 1995, 57(5):726-730.
7. Falini B., Pileri S., Pizzolo G., et al. CD30 (ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995, 85(1):1-14.
8. Sotlar K., Cerny-Reiterer S., Petat-Dutter K., et al. Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. Mod Pathol 2011, 24(4):585-595.
9. Aizawa S., Satoh H., Horie R., et al. Cloning and characterization of a cDNA for rat CD30 homolog and chromosomal assignment of the genomic gene. Gene 1996, 182(1-2):155-162.
10. Fonatsch C., Latza U., Durkop H., et al. Assignment of the human CD30 (ki-1) gene to 1p36. Genomics 1992, 14(3):825-826.
11. Froese P., Lemke H., Gerdes J., et al. Biochemical characterization and biosynthesis of the ki-1 antigen in Hodgkin-derived and virus-transformed human B and T lymphoid cell lines. JImmunol 1987, 139(6):2081-2087.
12. Horie R., Ito K., Tatewaki M., et al. Avariant CD30 protein lacking extracellular and transmembrane domains is induced in HL-60 by tetradecanoylphorbol acetate and is expressed in alveolar macrophages. Blood 1996, 88(7):2422-2432.
13. Schneider C., Hubinger G. Pleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) family. Leuk Lymphoma 2002, 43(7):1355-1366.
14. Wiley S.R., Goodwin R.G., Smith C.A. Reverse signaling via CD30 ligand. JImmunol 1996, 157(8):3635-3639.
15. Eichenauer D.A., Simhadri V.L., von Strandmann E.P., et al. ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy invitro. Cancer Res 2007, 67(1):332-338.
16. Hansen H.P., Dietrich S., Kisseleva T., et al. CD30 shedding from karpas 299 lymphoma cells is mediated by TNF-alpha-converting enzyme. JImmunol 2000, 165(12):6703-6709.
17. Rossi F.M., Degan M., Mazzocut-Zecchin L., et al. CD30L up-regulates CD30 and IL-4 expression by T cells. FEBS Lett 2001, 508(3):418-422.
18. Hargreaves P.G., Al-Shamkhani A. Soluble CD30 binds to CD153 with high affinity and blocks transmembrane signaling by CD30. Eur J Immunol 2002, 32(1):163-173.
19. Hansen H.P., Recke A., Reineke U., et al. The ectodomain shedding of CD30 is specifically regulated by peptide motifs in its cysteine-rich domains 2 and 5. FASEB J 2004, 18(7):893-895.
20. Saraiva M., Smith P., Fallon P.G., et al. Inhibition of type 1 cytokine-mediated inflammation by a soluble CD30 homologue encoded by ectromelia (mousepox) virus. JExp Med 2002, 196(6):829-839.
21. Powell I.F., Li T., Jack H.M., et al. Construction and expression of a soluble form of human CD30 ligand with functional activity. JLeukoc Biol 1998, 63(6):752-757.
22. Tamiolakis D., Maroulis G., Simopoulos C., et al. Human embryonal tissues of all three germ layers can express the CD30 antigen. an immunohistochemical study of 30 fetuses coming after therapeutic abortions from week 8th to week 16th of gestation. Cesk Patol 2006, 42(1):9-15.
23. Kennedy M.K., Willis C.R., Armitage R.J. Deciphering CD30 ligand biology and its role in humoral immunity. Immunology 2006, 118(2):143-152.
24. Lane P.J., Gaspal F.M., Kim M.Y. Two sides of a cellular coin: CD4(+)CD3- cells regulate memory responses and lymph-node organization. Nat Rev Immunol 2005, 5(8):655-660.
25. Gruss H.J., Pinto A., Gloghini A., et al. CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues. Am J Pathol 1996, 149(2):469-481.
26. Andreesen R., Brugger W., Lohr G.W., et al. Human macrophages can express the Hodgkin's cell-associated antigen ki-1 (CD30). Am J Pathol 1989, 134(1):187-192.
27. Durkop H., Foss H.D., Eitelbach F., et al. Expression of the CD30 antigen in non-lymphoid tissues and cells. JPathol 2000, 190(5):613-618.
28. Ellis T.M., Simms P.E., Slivnick D.J., et al. CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. JImmunol 1993, 151(5):2380-2389.
29. Klein U., Tu Y., Stolovitzky G.A., et al. Transcriptional analysis of the B cell germinal center reaction. Proc Natl Acad Sci USA 2003, 100(5):2639-2644.
30. Feldhahn N., Schwering I., Lee S., et al. Silencing of B cell receptor signals in human naive B cells. JExp Med 2002, 196(10):1291-1305.
31. Schwarting R., Gerdes J., Durkop H., et al. BER-H2: A new anti-ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood 1989, 74(5):1678-1689.
32. Cerutti A., Schaffer A., Goodwin R.G., et al. Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD+ IgM+ B cells. JImmunol 2000, 165(2):786-794.
33. Bekiaris V., Gaspal F., McConnell F.M., et al. NK cells protect secondary lymphoid tissue from cytomegalovirus via a CD30-dependent mechanism. Eur J Immunol 2009, 39(10):2800-2808.
34. Simhadri V.L., Hansen H.P., Simhadri V.R., et al. Anovel role for reciprocal CD30-CD30L signaling in the cross-talk between natural killer and dendritic cells. Biol Chem 2012, 393(1-2):101-106.
35. Cattoretti G., Buttner M., Shaknovich R., et al. Nuclear and cytoplasmic AID in extrafollicular and germinal center B cells. Blood 2006, 107(10):3967-3975.
36. Romagnani P., Annunziato F., Manetti R., et al. High CD30 ligand expression by epithelial cells and Hassal's corpuscles in the medulla of human thymus. Blood 1998, 91(9):3323-3332.
37. Matsumoto K., Terakawa M., Miura K., et al. Extremely rapid and intense induction of apoptosis in human eosinophils by anti-CD30 antibody treatment invitro. JImmunol 2004, 172(4):2186-2193.
38. Pinto A., Aldinucci D., Gloghini A., et al. Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. Blood 1996, 88(9):3299-3305.
39. Tamiolakis D., Papadoupoulos N., Venizelos I., et al. CD30 (ki-1) molecule expression in human embryonal epithelial cells of the basal layer of the developing epidermis and epidermal buds and its potential significance for embryogenesis. Acta Dermatovenerol Alp Panonica Adriat 2005, 14(3):85-90. 92.
40. Ito K., Watanabe T., Horie R., et al. High expression of the CD30 molecule in human decidual cells. Am J Pathol 1994, 145(2):276-280.
41. Oflazoglu E., Grewal I.S., Gerber H. Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. Adv Exp Med Biol 2009, 647:174-185.
42. Di Lorenzo G., Gangemi S., Merendino R.A., et al. Serum levels of soluble CD30 in adult patients affected by atopic dermatitis and its relation to age, duration of disease and scoring atopic dermatitis index. Mediators Inflamm 2003, 12(2):123-125.
43. Foschi F.G., Emiliani F., Savini S., et al. CD30 serum levels and response to hymenoptera venom immunotherapy. JInvestig Allergol Clin Immunol 2008, 18(4):279-283.
44. Phenekos C., Vryonidou A., Gritzapis A.D., et al. Th1 and Th2 serum cytokine profiles characterize patients with Hashimoto's thyroiditis (Th1) and graves' disease (Th2). Neuroimmunomodulation 2004, 11(4):209-213.
45. Somada S., Muta H., Nakamura K., et al. CD30 ligand/CD30 interaction is involved in pathogenesis of inflammatory bowel disease. Dig Dis Sci 2012, 57(8):2031-2037.
46. Wang G., Hansen H., Tatsis E., et al. High plasma levels of the soluble form of CD30 activation molecule reflect disease activity in patients with Wegener's granulomatosis. Am J Med 1997, 102(6):517-523.
47. Moonim M, Kossier T, van Der Walt J, etal. CD30/CD123 expression in systemic mastocytosis does not correlate with aggressive disease. Poster presented at: 54th Annual Meeting of the American Society of Hematology. Atlanta, GA, December 8, 2012.
48. Chiu A., Czader M.B., Ochs R.C., et al. Subtypes of systemic mastocytosis exhibit distinct immunomorphologic features in bone marrow biopsies. Lab Invest 2013, 93:324A.
49. Arredondo A.R., Jennings C.D., Shier L., et al. CD30 expression in mastocytosis. Lab Invest 2011, 91:285A-286A.
50. Delsol G., Jaffe E., Falini B. Anaplastic large cell lymphoma (ALCL), ALK-positive. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, 312-316. IARC, Lyon (France). 4th edition. S. Swerdlow, E. Campo, N. Harris (Eds.).
51. Hu S., Xu-Monette Z.Y., Balasubramanyam A., et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the international DLBCL rituximab-CHOP consortium program study. Blood 2013, 121(14):2715-2724.
52. Kadin M.E., Pavlov I.Y., Delgado J.C., et al. High soluble CD30, CD25, and IL-6 may identify patients with worse survival in CD30+ cutaneous lymphomas and early mycosis fungoides. JInvest Dermatol 2012, 132(3 Pt 1):703-710.
53. Nadali G., Tavecchia L., Zanolin E., et al. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood 1998, 91(8):3011-3016.
54. Visco C., Nadali G., Vassilakopoulos T.P., et al. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. Eur J Haematol 2006, 77(5):387-394.
55. von Wasielewski R., Mengel M., Fischer R., et al. Classical Hodgkin's disease. clinical impact of the immunophenotype. Am J Pathol 1997, 151(4):1123-1130.
56. Delabie J., Holte H., Vose J.M., et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood 2011, 118(1):148-155.
57. Gardner L.J., Polski J.M., Evans H.L., et al. CD30 expression in follicular lymphoma. Arch Pathol Lab Med 2001, 125(8):1036-1041.
58. Kempf W., Pfaltz K., Vermeer M.H., et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: Lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 2011, 118(15):4024-4035.
59. Pileri S.A., Gaidano G., Zinzani P.L., et al. Primary mediastinal B-cell lymphoma: High frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. Am J Pathol 2003, 162(1):243-253.
60. Leroy X., Augusto D., Leteurtre E., et al. CD30 and CD117 (c-kit) used in combination are useful for distinguishing embryonal carcinoma from seminoma. JHistochem Cytochem 2002, 50(2):283-285.
61. Ansari M.Q., Dawson D.B., Nador R., et al. Primary body cavity-based AIDS-related lymphomas. Am J Clin Pathol 1996, 105(2):221-229.
62. Morgado J.M., Perbellini O., Johnson R.C., et al. CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis. Histopathology 2013, 63(6):780-787.
63. Zheng W., Medeiros L.J., Hu Y., et al. CD30 expression in high-risk acute myeloid leukemia and myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk 2013, 13(3):307-314.
64. Hong J., Park S., Baek H.L., et al. Tumor cell nuclear diameter and CD30 expression as potential prognostic parameter in patients with extranodal NK/T-cell lymphoma, nasal type. Int J Clin Exp Pathol 2012, 5(9):939-947.
65. Benner M.F., Jansen P.M., Vermeer M.H., et al. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood 2012, 119(7):1643-1649.
66. Takeshita M., Akamatsu M., Ohshima K., et al. CD30 (ki-1) expression in adult T-cell leukaemia/lymphoma is associated with distinctive immunohistological and clinical characteristics. Histopathology 1995, 26(6):539-546.
67. Nishioka C., Takemoto S., Kataoka S., et al. Serum level of soluble CD30 correlates with the aggressiveness of adult T-cell leukemia/lymphoma. Cancer Sci 2005, 96(11):810-815.
68. Kanavaros P., Jiwa N.M., de Bruin P.C., et al. High incidence of EBV genome in CD30-positive non-Hodgkin's lymphomas. JPathol 1992, 168(3):307-315.
69. Herbst H., Stein H. Tumor viruses in CD30-positive anaplastic large cell lymphomas. Leuk Lymphoma 1993, 9(4-5):321-328.
70. Niedobitek G. The role of Epstein-Barr virus in the pathogenesis of Hodgkin's disease. Ann Oncol 1996, 7(Suppl 4):11-17.
71. Zheng B., Fiumara P., Li Y.V., et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 2003, 102(3):1019-1027.
72. Guo F., Sun A., Wang W., et al. TRAF1 is involved in the classical NF-kappaB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells. Mol Immunol 2009, 46(13):2441-2448.
73. Hirsch B., Hummel M., Bentink S., et al. CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells. Am J Pathol 2008, 172(2):510-520.
74. Staber P.B., Noehammer C., Durkop H., et al. mRNA expression patterns indicate CD30 mediated activation of different apoptosis pathways in anaplastic large cell lymphoma but not in Hodgkin's lymphoma. Leuk Res 2006, 30(3):343-348.
75. Horn-Lohrens O., Tiemann M., Lange H., et al. Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (ki-4). Int J Cancer 1995, 60(4):539-544.
76. Withers D.R., Gaspal F.M., Bekiaris V., et al. OX40 and CD30 signals in CD4(+) T-cell effector and memory function: a distinct role for lymphoid tissue inducer cells in maintaining CD4(+) T-cell memory but not effector function. Immunol Rev 2011, 244(1):134-148.
77. Gaspal F.M., Kim M.Y., McConnell F.M., et al. Mice deficient in OX40 and CD30 signals lack memory antibody responses because of deficient CD4 T cell memory. JImmunol 2005, 174(7):3891-3896.
78. Shanebeck K.D., Maliszewski C.R., Kennedy M.K., et al. Regulation of murine B cell growth and differentiation by CD30 ligand. Eur J Immunol 1995, 25(8):2147-2153.
79. Polte T., Fuchs L., Behrendt A.K., et al. Different role of CD30 in the development of acute and chronic airway inflammation in a murine asthma model. Eur J Immunol 2009, 39(7):1736-1742.
80. Nam S.Y., Kim Y.H., Do J.S., et al. CD30 supports lung inflammation. Int Immunol 2008, 20(2):177-184.
81. Fuchiwaki T., Sun X., Fujimura K., et al. The central role of CD30L/CD30 interactions in allergic rhinitis pathogenesis in mice. Eur J Immunol 2011, 41(10):2947-2954.
82. Molin D., Fischer M., Xiang Z., et al. Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease. Br J Haematol 2001, 114(3):616-623.
83. Fischer M., Harvima I.T., Carvalho R.F., et al. Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. JClin Invest 2006, 116(10):2748-2756.
84. Su C.C., Chiu H.H., Chang C.C., et al. CD30 is involved in inhibition of T-cell proliferation by Hodgkin's Reed-Sternberg cells. Cancer Res 2004, 64(6):2148-2152.
85. Cerutti A., Kim E.C., Shah S., et al. Dysregulation of CD30+ T cells by leukemia impairs isotype switching in normal B cells. Nat Immunol 2001, 2(2):150-156.
86. Polte T., Behrendt A.K., Hansen G. Direct evidence for a critical role of CD30 in the development of allergic asthma. JAllergy Clin Immunol 2006, 118(4):942-948.
87. Muller U., Helbling A., Hunziker T., et al. Mastocytosis and atopy: a study of 33 patients with urticaria pigmentosa. Allergy 1990, 45(8):597-603.
88. Horny H.P., Metcalfe D.D., Bennett J.M., et al. Mastocytosis. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, 54-63. IARC Press, Lyon (France). S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
89. van Anrooij B., van der Veer E., de Monchy J.G., et al. Higher mast cell load decreases the risk of hymenoptera venom-induced anaphylaxis in patients with mastocytosis. JAllergy Clin Immunol 2013, 132(1):125-130.
90. Bartlett N.L., Younes A., Carabasi M.H., et al. Aphase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2008, 111(4):1848-1854.
91. Ansell S.M., Horwitz S.M., Engert A., et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. JClin Oncol 2007, 25(19):2764-2769.
92. Younes A., Bartlett N.L., Leonard J.P., et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. NEngl J Med 2010, 363(19):1812-1821.
93. de Claro R.A., McGinn K., Kwitkowski V., et al. U.S. food and drug administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res 2012, 18(21):5845-5849.